IOL Chemicals and Pharmaceuticals (IOLCP) has completed its De-bottlenecking/ Re-engineering project for its Ibuprofen Manufacturing facilities at Barnala with project cost of Rs 24 crore and commenced the enhanced production from November 19, 2015. Post this completion, the capacity of Ibuprofen plant increased to 6200 TPA.
The Ibuprofen manufacturing facilities have been approved by US Food and Drug Administration (USFDA), ANVISA, EDQM WHO & MOH Japan. The company is already exporting its Ibuprofen in regulated & Emerging markets i.e. Europe, Latin America, Middle East, etc and with the recent approval from USFDA, the company is expanding its business of Ibuprofen in USA.
The company’s manufacturing facilities hold CEP certification (Certificate of Suitability) for its products Ibuprofen, Metformin Hydrochloride & Lamotrigine from European Directorate for the Quality of Medicines & HealthCare (EDQM) authorities, Council of Europe, France. These approvals will facilitate the company to build and sustaining the growth by its API business in coming years, being the only integrated Ibuprofen player globally, by exploring the higher value regulated markets.
IOL Chemicals & Pharmaceuticals is one of the largest manufacturers of APIs and specialty chemicals with presence in over 57 countries across the world. It manufactures and supplies APIs and specialty chemicals for use in various pharmaceutical, textile, packaging, lamination, pesticides and food processing applications.
